Catalogo Articoli (Spogli Riviste)

HELP
ATTENZIONE: attualmente gli articoli Current Contents (fonte ISI) a partire dall'anno 2002 sono consultabili sulla Risorsa On-Line

Le informazioni sugli articoli di fonte ISI sono coperte da copyright

La ricerca find articoli where authors phrase all words ' Lejeune, F' sort by level,fasc_key/DESCEND, pagina_ini_num/ASCEND ha restituito 95 riferimenti
Selezionare un intervallo

Per ulteriori informazioni selezionare i riferimenti di interesse.

    1. Pittet, MJ; Speiser, DE; Valmori, D; Rimoldi, D; Lienard, D; Lejeune, F; Cerottini, JC; Romero, P
      Ex vivo analysis of tumor antigen specific CD8(+) T cell responses using MHC/peptide tetramers in cancer patients

      INTERNATIONAL IMMUNOPHARMACOLOGY
    2. Pittet, MJ; Speiser, DE; Lienard, D; Valmori, D; Guillaume, P; Dutoit, V; Rimoldi, D; Lejeune, F; Cerottini, JC; Romero, P
      Expansion and functional maturation of human tumor antigen-specific CD8(+)T cells after vaccination with antigenic peptide

      CLINICAL CANCER RESEARCH
    3. Vouillamoz-Lorenz, S; Bauer, J; Lejeune, F; Decosterd, LA
      Validation of an AAS method for the determination of platinum in biological fluids from patients receiving the oral platinum derivative JM216

      JOURNAL OF PHARMACEUTICAL AND BIOMEDICAL ANALYSIS
    4. Brand, M; Moggs, JG; Oulad-Abdelghani, M; Lejeune, F; Dilworth, FJ; Stevenin, J; Almouzni, G; Tora, L
      UV-damaged DNA-binding protein in the TFTC complex links DNA damage recognition to nucleosome acetylation

      EMBO JOURNAL
    5. Rubio-Godoy, V; Dutoit, V; Rimoldi, D; Lienard, D; Lejeune, F; Speiser, D; Guillaume, P; Cerottini, JC; Romero, P; Valmori, D
      Discrepancy between ELISPOT IFN-gamma secretion and binding of A2/peptide multimers to TCR reveals interclonal dissociation of CTL effector function from TCR-peptide/MHC complexes half-life

      PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
    6. Millan, MJ; Gobert, A; Lejeune, F; Newman-Tancredi, A; Rivet, JM; Auclair, A; Peglion, JL
      S33005, a novel ligand at both serotonin and norepinephrine transporters: I. Receptor binding, electrophysiological, and neurochemical profile in comparison with venlafaxine, reboxetine, citalopram, and clomipramine

      JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS
    7. Millan, MJ; Cussac, D; Milligan, G; Carr, C; Audinot, V; Gobert, A; Lejeune, F; Rivet, JM; Brocco, M; Duqueyroix, D; Nicolas, JP; Boutin, JA; Newman-Tancredi, A
      Antiparkinsonian agent piribedil displays antagonist properties at native,rat, and cloned, human alpha(2)-adrenoceptors: Cellular and functional characterization

      JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS
    8. Millan, MJ; Lejeune, F; De Nanteuil, G; Gobert, A
      Selective blockade of neurokinin (NK)(1) receptors facilitates the activity of adrenergic pathways projecting to frontal cortex and dorsal hippocampus in rats

      JOURNAL OF NEUROCHEMISTRY
    9. Pittet, MJ; Zippelius, A; Speiser, DE; Assenmacher, M; Guillaume, P; Valmori, D; Lienard, D; Lejeune, F; Cerottini, JC; Romero, P
      Ex vivo IFN-gamma secretion by circulating CD8 T lymphocytes: Implicationsof a novel approach for T cell monitoring in infectious and malignant diseases

      JOURNAL OF IMMUNOLOGY
    10. Le Guienr, C; Lejeune, F; Galiana, D; Kister, L; Breathnach, R; Stevenin, J; Del Gatto-Konczak, F
      TIA-1 and TIAR activate splicing of alternative exons with weak 5 ' splicesites followed by a U-rich stretch on their own pre-mRNAs

      JOURNAL OF BIOLOGICAL CHEMISTRY
    11. Lejeune, F; Cavaloc, Y; Stevenin, J
      Alternative splicing of intron 3 of the serine/arginine-rich protein 9G8 gene - Identification of flanking exonic splicing enhancers and involvement of 9G8 as a trans-acting factor

      JOURNAL OF BIOLOGICAL CHEMISTRY
    12. Ghanem, G; Loir, B; Morandini, R; Sales, F; Lienard, D; Eggermont, A; Lejeune, F
      On the release and half-life of S100B protein in the peripheral blood of melanoma patients

      INTERNATIONAL JOURNAL OF CANCER
    13. Speiser, DE; Migliaccio, M; Pittet, MJ; Valmori, D; Lienard, D; Lejeune, F; Reichenbach, P; Guillaume, P; Luscher, I; Cerottini, JC; Romero, P
      Human CD8(+) T cells expressing HLA-DR and CD28 show telomerase activity and are distinct from cytolytic effector T cells

      EUROPEAN JOURNAL OF IMMUNOLOGY
    14. Lejeune, F; Millan, MJ
      Pindolol excites dopaminergic and adrenergic neurons, and inhibits serotonergic neurons, by activation of 5-HT1A receptors

      EUROPEAN JOURNAL OF NEUROSCIENCE
    15. Millan, MJ; Gobert, A; Rivet, JM; Adhumeau-Auclair, A; Cussac, D; Newman-Tancredi, A; Dekeyne, A; Nicolas, JP; Lejeune, F
      Mirtazapine enhances frontocortical dopaminergic and corticolimbic adrenergic, but not serotonergic, transmission by blockade of alpha(2)-adrenergic and serotonin(2C) receptors: a comparison with citalopram

      EUROPEAN JOURNAL OF NEUROSCIENCE
    16. Gobert, A; Rivet, JM; Lejeune, F; Newman-Tancredi, A; Adhumeau-Auclair, A; Nicolas, JP; Cistarelli, L; Melon, C; Millan, MJ
      Serotonin(2C) receptors tonically suppress the activity of mesocortical dopaminergic and adrenergic, but not serotonergic, pathways: A combined dialysis and electrophysiological analysis in the rat

      SYNAPSE
    17. Millan, MJ; Newman-Tancredi, A; Audinot, V; Cussac, D; Lejeune, F; Nicolas, JP; Coge, F; Galizzi, JP; Boutin, JA; Rivet, JM; Dekeyne, A; Gobert, A
      Agonist and antagonist actions of yohimbine as compared to fluparoxan at alpha(2)-adrenergic receptors (AR)s, serotonin (5-HT)(1A), 5-HT1B, 5-HT1D and dopamine D-2 and D-3 receptors. Significance for the modulation of frontocortical monoaminergic transmission and depressive states

      SYNAPSE
    18. Millan, MJ; Lejeune, F; Gobert, A
      Reciprocal autoreceptor and heteroreceptor control of serotonergic, dopaminergic and noradrenergic transmission in the frontal cortex: relevance to the actions of antidepressant agents

      JOURNAL OF PSYCHOPHARMACOLOGY
    19. Millan, MJ; Lejeune, F; Gobert, A; Brocco, M; Auclair, A; Bosc, C; Rivet, JM; Lacoste, JM; Cordi, A; Dekeyne, A
      S18616, a highly potent spiroimidazoline agonist at alpha(2)-adrenoceptors: II. Influence on monoaminergic transmission, motor function, and anxiety in comparison with dexmedetomidine and clonidine

      JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS
    20. Millan, MJ; Gobert, A; Newman-Tancredi, A; Lejeune, F; Cussac, D; Rivet, JM; Audinot, V; Dubuffet, T; Lavielle, G
      S33084, a novel, potent, selective, and competitive antagonist at dopamineD-3-receptors: I. Receptorial, electrophysiological and neurochemical profile compared with GR218,231 and L741,626

      JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS
    21. Millan, MJ; Gobert, A; Newman-Tancredi, A; Lejeune, F; Cussac, D; Rivet, JM; Audinot, V; Adhumeau, A; Brocco, M; Nicolas, JP; Boutin, JA; Despaux, N; Peglion, JL
      S18327 (1-{2-[4-(6-fluoro-1,2-benzisoxazol-3-yl)piperid-1-yl]ethyl}3-phenyl imidazolin-2-one), a novel, potential antipsychotic displaying marked antagonist properties at alpha(1) and alpha(2)-adrenergic receptors: I. Receptorial, neurochemical, and electrophysiological profile

      JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS
    22. Rimoldi, D; Rubio-Godoy, V; Dutoit, V; Lienard, D; Salvi, S; Guillaume, P; Speiser, D; Stockert, E; Spagnoli, G; Servis, C; Cerottini, JC; Lejeune, F; Romero, P; Valmori, D
      Efficient simultaneous presentation of NY-ESO-1/LAGE-1 primary and nonprimary open reading frame-derived CTL epitopes in melanoma

      JOURNAL OF IMMUNOLOGY
    23. Valmori, D; Dutoit, V; Lienard, D; Lejeune, F; Speiser, D; Rimoldi, D; Cerundolo, V; Dietrich, PY; Cerottini, JC; Romero, P
      Tetramer-guided analysis of TCR beta-chain usage reveals a large repertoire of melan-A-specific CD8(+) T cells in melanoma patients

      JOURNAL OF IMMUNOLOGY
    24. Valmori, D; Dutoit, V; Lienard, D; Rimoldi, D; Pittet, MJ; Champagne, P; Ellefsen, K; Sahin, U; Speiser, D; Lejeune, F; Cerottini, JC; Romero, P
      Naturally occurring human lymphocyte antigen-A2 restricted CD8+T-cell response to the cancer testis antigen NY-ESO-1 in melanoma patients

      CANCER RESEARCH
    25. Kettaneh, A; Fain, O; Ziol, M; Lejeune, F; Eclache-Saudreau, V; Biaggi, A; Guettier-Bouttier, C; Thomas, M
      Minocycline-induced systemic adverse reaction with liver and bone marrow granulomas and Sezary-like cells

      AMERICAN JOURNAL OF MEDICINE
    26. Ruegg, C; Oguey, D; Lejeune, F
      Death to endothelial cells, death to melanoma?

      MELANOMA RESEARCH
    27. Gander, M; Leyvraz, S; Decosterd, L; Bonfanti, M; Marzolini, C; Shen, F; Lienard, D; Perey, L; Colella, G; Biollaz, J; Lejeune, F; Yarosh, D; Belanich, M; D'Incalci, M
      Sequential administration of temozolomide and fotemustine: Depletion of O-6-alkyl guanine-DNA transferase in blood lymphocytes and in tumours

      ANNALS OF ONCOLOGY
    28. Marzolini, C; Decosterd, LA; Shen, F; Gander, M; Leyvraz, S; Bauer, J; Buclin, T; Biollaz, J; Lejeune, F
      Pharmacokinetics of temozolomide in association with fotemustine in malignant melanoma and malignant glioma patients: comparison of oral, intravenous, and hepatic intra-arterial administration (vol 42, pg 433, 1998)

      CANCER CHEMOTHERAPY AND PHARMACOLOGY
    29. Pittet, MJ; Valmori, D; Dunbar, PR; Speiser, DE; Lienard, D; Lejeune, F; Fleischhauer, K; Cerundolo, V; Cerottini, JC; Romero, P
      High frequencies of naive Melan-A/MART-1-specific CD8(+) T cells in a large proportion of human histocompatibility leukocyte antigen (HLA)-A2 individuals

      JOURNAL OF EXPERIMENTAL MEDICINE
    30. Valmori, D; Pittet, MJ; Rimoldi, D; Lienard, D; Dunbar, R; Cerundolo, V; Lejeune, F; Cerottini, JC; Romero, P
      An antigen-targeted approach to adoptive transfer therapy of cancer

      CANCER RESEARCH
    31. Decosterd, LA; Cottin, E; Chen, X; Lejeune, F; Mirimanoff, RO; Biollaz, J; Coucke, PA
      Simultaneous determination of deoxyribonucleoside in the presence of ribonucleoside triphosphates in human carcinoma cells by high-performance liquidchromatography

      ANALYTICAL BIOCHEMISTRY
    32. ANDRIEU JM; JAIS JP; COLONNA P; DESABLENS B; BRIERE J; FRANCOIS S; HAROUSSEAU JL; CASASSUS P; LEMEVEL A; LEPRISE PY; GHANDOUR C; GUILHOT F; LEJEUNE F
      10-YEAR RESULTS OF A STRATEGY COMBINING 3 CYCLES OF ABVD AND HIGH-DOSE EXTENDED IRRADIATION FOR TREATING HODGKINS-DISEASE AT ADVANCED STAGES

      Annals of oncology
    33. VOUILLAMOZLORENZ S; DECOSTERD LA; BAUER J; BUCLIN T; LEJEUNE F
      A PHASE-I PHARMACOKINETIC (PK) STUDY OF THE ORAL PLATINUM (PT) ANALOGJM216 ADMINISTERED ONCE-A-DAY OVER 14 DAYS

      Annals of oncology
    34. LEJEUNE F; MILLAN MJ
      INDUCTION OF BURST FIRING IN VENTRAL TEGMENTAL AREA DOPAMINERGIC-NEURONS BY ACTIVATION OF SEROTONIN (5-HT)(1A) RECEPTORS - WAY 100,635-REVERSIBLE ACTIONS OF THE HIGHLY SELECTIVE LIGANDS, FLESINOXAN AND S-15535

      Synapse
    35. MARZOLINI C; DECOSTERD LA; SHEN F; GANDER M; LEYVRAZ S; BAUER J; BUCLIN T; BIOLLAZ J; LEJEUNE F
      PHARMACOKINETICS OF TEMOZOLOMIDE IN ASSOCIATION WITH FOTEMUSTINE IN MALIGNANT-MELANOMA AND MALIGNANT GLIOMA PATIENTS - COMPARISON OF ORAL, INTRAVENOUS, AND HEPATIC INTRAARTERIAL ADMINISTRATION

      Cancer chemotherapy and pharmacology
    36. MILLAN MJ; NEWMANTANCREDI A; BROCCO N; GOBERT A; LEJEUNE F; AUDINOT V; RIVET JM; SCHREIBER R; DEKEYNE A; SPEDDING M; NICOLAS JP; PEGLION JL
      S-18126 4-(2,3-DIHYDROBENZO[1,4]DIOXIN-6-YL)PIPERAZIN-1-YL METHYL]INDAN-2-YL)), A POTENT, SELECTIVE AND COMPETITIVE ANTAGONIST AT DOPAMINE D-4 RECEPTORS - AN IN-VITRO AND IN-VIVO COMPARISON WITH L-745,870 YL]PIPERAZIN-1-YL)METHYL-1H-PYRROLO[2,3B]PYRIDINE) AND RACLOPRIDE

      The Journal of pharmacology and experimental therapeutics
    37. AUDINOT V; NEWMANTANCREDI A; GOBERT A; RIVET JM; BROCCO M; LEJEUNE F; GLUCK L; DESPOSTE I; BERVOETS K; DEKEYNE A; MILLAN MJ
      A COMPARATIVE IN-VITRO AND IN-VIVO PHARMACOLOGICAL CHARACTERIZATION OF THE NOVEL DOPAMINE D-3 RECEPTOR ANTAGONISTS (-S-14297, NAFADOTRIDE, GR-103,691 AND U-99194())

      The Journal of pharmacology and experimental therapeutics
    38. MILLAN MJ; GOBERT A; NEWMANTANCREDI A; AUDINOT V; LEJEUNE F; RIVET JM; CUSSAC D; NICOLAS JP; MULLER O; LAVIELLE G
      S-16924 YL]-PYRROLIDIN-3YL)-1-(4-FLUORO-PHENYL)-ETHANONE), A NOVEL POTENTIAL ANTIPSYCHOTIC WITH MARKED SEROTONIN (5-HT)(1A) AGONIST PROPERTIES - I - RECEPTORIAL AND NEUROCHEMICAL PROFILE COMPARISON WITH CLOZAPINE AND HALOPERIDOL

      The Journal of pharmacology and experimental therapeutics
    39. DSOUZA S; RIMOLDI D; LIENARD D; LEJEUNE F; CEROTTINI JC; ROMERO P
      CIRCULATING MELAN-A MART-1 SPECIFIC CYTOLYTIC T-LYMPHOCYTE PRECURSORSIN HLA-A2(+) MELANOMA PATIENTS HAVE A MEMORY PHENOTYPE/

      International journal of cancer
    40. NAJEAN Y; RAIN JD; LEJEUNE F; ECHARD M; FERMAND JP; GRUYER P; BRAHIMI S
      TREATMENT OF POLYCYTHEMIA - II - RANDOMIZ ED PROTOCOL IN POLYCYTHEMIA-VERA PATIENTS COMPARING HYDROXYUREA AND PIPOBROMAN

      Annales de medecine interne
    41. LEJEUNE F; LIENARD D; EGGERMONT A
      REGIONAL ADMINISTRATION OF RECOMBINANT TUMOR-NECROSIS-FACTOR-ALPHA INCANCER, WITH SPECIAL REFERENCE TO MELANOMA

      Biodrugs
    42. KEILHOLZ U; STOTER G; PUNT CJA; SCHEIBENBOGEN C; LEJEUNE F; EGGERMONT AMM
      RECOMBINANT INTERLEUKIN-2-BASED TREATMENTS FOR ADVANCED MELANOMA - THE EXPERIENCE OF THE EUROPEAN ORGANIZATION FOR RESEARCH AND TREATMENT OF CANCER MELANOMA COOPERATIVE GROUP

      The cancer journal from Scientific American
    43. WAANDERS GA; RIMOLDI D; LIENARD D; CARREL S; LEJEUNE F; DIETRICH PY; CEROTTINI JC; ROMERO P
      MELANOMA-REACTIVE HUMAN CYTOTOXIC T-LYMPHOCYTES DERIVED FROM SKIN BIOPSIES OF DELAYED-TYPE HYPERSENSITIVITY REACTIONS INDUCED BY INJECTION OF AN AUTOLOGOUS MELANOMA CELL-LINES (VOL 3, PG 685, 1997)

      Clinical cancer research
    44. WAANDERS GA; RIMOLDI D; LIENARD D; CARREL S; LEJEUNE F; DIETRICH PY; CEROTTINI JC; ROMERO P
      MELANOMA-REACTIVE HUMAN CYTOTOXIC T-LYMPHOCYTES DERIVED FROM SKIN BIOPSIES OF DELAYED-TYPE HYPERSENSITIVITY REACTIONS INDUCED BY INJECTION OF AN AUTOLOGOUS MELANOMA CELL-LINE

      Clinical cancer research
    45. GERAIN J; LIENARD D; PAMPALLONA S; BAUMGARTNER M; RUEGG C; BUURMAN WA; EGGERMONT A; LEJEUNE F
      SYSTEMIC RELEASE OF SOLUBLE TNF RECEPTORS AFTER HIGH-DOSE TNF IN ISOLATED LIMB PERFUSION

      Cytokine
    46. LEJEUNE F; KOOPS HS; KROON B; EGGERMONT A
      REGIONAL THERAPY FOR MELANOMA - RANDOMIZED TRIALS

      European journal of cancer
    47. LEYVRAZ S; SPATARO V; BAUER J; PAMPALLONA S; SALMON R; DORVAL T; MEULI R; GILLET M; LEJEUNE F; ZOGRAFOS L
      TREATMENT OF OCULAR MELANOMA METASTATIC TO THE LIVER BY HEPATIC ARTERIAL CHEMOTHERAPY

      Journal of clinical oncology
    48. LEJEUNE F; NEWMANTANCREDI A; AUDINOT V; MILLAN MJ
      INTERACTIONS OF (-HYDROXY-2-(DI-N-PROPYLAMINO)TETRALIN AND (-)-8-HYDROXY-2-(DI-N-PROPYLAMINO)TETRALIN AND 7-HYDROXY-2-(DI-N-PROPYLAMINO)TETRALIN AT HUMAN (H)D-3, HD(2) AND H-SEROTONIN(1A) RECEPTORS AND THEIR MODULATION OF THE ACTIVITY OF SEROTONINERGIC AND DOPAMINERGIC-NEURONS IN RATS())

      The Journal of pharmacology and experimental therapeutics
    49. AUTIER P; DORE JF; GEFELLER O; CESARINI JP; LEJEUNE F; KOELMEL KF; LIENARD D; KLEEBERG UR
      MELANOMA RISK AND RESIDENCE IN SUNNY AREAS

      British Journal of Cancer
    50. TCHERNIA G; LEJEUNE F; BOCCARA JF; DENAVIT MF; DOMMERGUES JP; BERNAUDIN F
      ERYTHROBLASTIC AND OR MEGAKARYOBLASTIC LEUKEMIA IN DOWN-SYNDROME - TREATMENT WITH LOW-DOSE ARABINOSYL CYTOSINE/

      Journal of pediatric hematology/oncology
    51. NAJEAN Y; RAIN JD; DRESCH C; GOGUEL A; LEJEUNE F; ECHARD M; GRANGE MJ
      RISK OF LEUKEMIA, CARCINOMA, AND MYELOFIBROSIS IN P-32-TREATED OR CHEMOTHERAPY-TREATED PATIENTS WITH POLYCYTHEMIA-VERA - A PROSPECTIVE ANALYSIS OF 682 CASES

      Leukemia & lymphoma
    52. BENHAMOU M; FEUILLARD J; LORTHOLARY O; BOURGEOIS C; MICHEL L; LEGOFF L; MICHEL A; MENCIAHUERTA JM; LEJEUNE F; CASASSUS P; DEBRE P; AROCK M
      PROTEIN-TYROSINE KINASES IN ACTIVATION SIGNAL OF HUMAN BASOPHILS THROUGH THE IMMUNOGLOBULIN-E RECEPTOR-TYPE-I

      Journal of leukocyte biology
    53. FAIN O; MATHIEU E; FETON N; SIBONY M; SITBON M; LEJEUNE F; THOMAS M
      INTESTINAL INVOLVEMENT IN SWEETS-SYNDROME

      Journal of the American Academy of Dermatology
    54. GOBERT A; LEJEUNE F; RIVET JM; CISTARELLI L; MILLAN MJ
      DOPAMINE D-3 (AUTO) RECEPTORS INHIBIT DOPAMINE RELEASE IN THE FRONTAL-CORTEX OF FREELY MOVING RATS IN-VIVO

      Journal of neurochemistry
    55. SHEN F; DECOSTERD LA; GANDER M; LEYVRAZ S; BIOLLAZ J; LEJEUNE F
      DETERMINATION OF TEMOZOLOMIDE IN HUMAN PLASMA AND URINE BY HIGH-PERFORMANCE LIQUID-CHROMATOGRAPHY AFTER SOLID-PHASE EXTRACTION

      Journal of chromatography B. Biomedical applications
    56. KLEEBERG UR; ENGEL E; ISRAELS P; BROCKER EB; TILGEN W; KENNES C; GERARD B; LEJEUNE F; GLABBEKE MV; LENTZ MA
      PALLIATIVE THERAPY OF MELANOMA PATIENTS WITH FOTEMUSTINE - INVERSE RELATIONSHIP BETWEEN TUMOR LOAD AND TREATMENT EFFECTIVENESS - A MULTICENTER PHASE-II TRIAL OF THE EORTC-MELANOMA COOPERATIVE GROUP (MCG)

      Melanoma research
    57. LEJEUNE F
      REGIONAL TREATMENT WITH TNF-ALPHA AND CHEMOTHERAPY

      European journal of cancer
    58. FOURNIER D; LEJEUNE F; TOURTE Y
      CYTOLOGICAL EVENTS DURING THE INITIATION OF MERISTEMATIC NODULES IN CALLI DERIVED FROM EGGPLANT PROTOPLASTS

      Biology of the cell
    59. GOBERT A; LEJEUNE F; RIVET JM; AUDINOT V; NEWMANTANCREDI A; MILLAN MJ
      MODULATION OF THE ACTIVITY OF CENTRAL SEROTONINERGIC NEURONS BY NOVELSEROTONIN(1A) RECEPTOR AGONISTS AND ANTAGONISTS - A COMPARISON TO ADRENERGIC AND DOPAMINERGIC-NEURONS IN RATS

      The Journal of pharmacology and experimental therapeutics
    60. MILLAN MJ; RIVET JM; AUDINOT V; GOBERT A; LEJEUNE F; BROCCO M; NEWMANTANCREDI A; MAURELREMY S; BERVOETS K
      ANTAGONIST PROPERTIES OF LY-165,163 AT PRESYNAPTIC AND POSTSYNAPTIC DOPAMINE D-2, D-3, AND D-1 RECEPTORS - MODULATION OF AGONIST ACTIONS AT5-HT1A RECEPTORS IN-VIVO

      The Journal of pharmacology and experimental therapeutics
    61. BRASSEUR F; RIMOLDI D; LIENARD D; LETHE B; CARREL S; ARIENTI F; SUTER L; VANWIJCK R; BOURLOND A; HUMBLET Y; VACCA A; CONESE M; LAHAYE T; DEGIOVANNI G; DERAEMAECKER R; BEAUDUIN M; SASTRE X; SALAMON E; DRENO B; JAGER E; KNUTH A; CHEVREAU C; SUCIU S; LACHAPELLE JM; POUILLART P; PARMIANI G; LEJEUNE F; CEROTTINI JC; BOON T; MARCHAND M
      EXPRESSION OF MAGE GENES IN PRIMARY AND METASTATIC CUTANEOUS MELANOMA

      International journal of cancer
    62. AUTIER P; DORE JF; SCHIFFLERS E; CESARINI JP; BOLLAERTS A; KOELMEL KF; GEFELLER O; LIABEUF A; LEJEUNE F; LIENARD D; JOARLETTE M; CHEMALY P; KLEEBERG UR
      MELANOMA AND USE OF SUNSCREENS - AN EORTC CASE-CONTROL STUDY IN GERMANY, BELGIUM AND FRANCE

      International journal of cancer
    63. LEJEUNE F; MILLAN MJ
      ACTIVATION OF DOPAMINE D-3 AUTORECEPTORS INHIBITS FIRING OF VENTRAL TEGMENTAL DOPAMINERGIC-NEURONS IN-VIVO

      European journal of pharmacology
    64. EGGIMANN P; CHIOLERO R; CHASSOT PG; LIENARD D; GERAIN J; LEJEUNE F
      SYSTEMIC AND HEMODYNAMIC-EFFECTS OF RECOMBINANT TUMOR-NECROSIS-FACTOR-ALPHA IN ISOLATION PERFUSION OF THE LIMBS

      Chest
    65. LEJEUNE F; LIENARD D; EGGERMONT A; KOOPS HS; ROSENKAIMER F; GERAIN J; KLAASE J; KROON B; SCHMITZ P
      EFFICACY OF TUMOR-NECROSIS-FACTOR-ALPHA ( RTNF-ALPHA) ASSOCIATED TO INTERFERON-GAMMA (IFN-GAMMA) AND TO CHEMOTHERAPY IN ISOLATED LIMB PERFUSION FOR INOPERABLE MALIGNANT-MELANOMA, SOFT-TISSUE SARCOMA AND EPIDERMOID CARCINOMA - A 4-YEAR EXPERIENCE

      Bulletin du cancer
    66. MAURELREMY S; AUDINOT V; LEJEUNE F; BERVOETS K; MILLAN MJ
      BLOCKADE OF PHENCYCLIDINE-INDUCED HYPERLOCOMOTION IN RATS BY CLOZAPINE, MDL-100,907 AND OTHER ANTIPSYCHOTICS CORRELATES WITH AFFINITY AT 5-HT2A RECEPTORS

      British Journal of Pharmacology
    67. BEGUIN Y; LOO M; RZIK S; SAUTOIS B; LEJEUNE F; RORIVE G; FILLET G
      QUANTITATIVE ASSESSMENT OF ERYTHROPOIESIS IN HEMODIALYSIS-PATIENTS DEMONSTRATES GRADUAL EXPANSION OF ERYTHROBLASTS DURING CONSTANT TREATMENT WITH RECOMBINANT-HUMAN-ERYTHROPOIETIN

      British Journal of Haematology
    68. LEYVRAZ S; KETTERER N; PEREY L; BAUER J; VUICHARD P; GROB JP; SCHNEIDER P; VONFLIEDNER V; LEJEUNE F; BACHMANN F
      INTENSIFICATION OF CHEMOTHERAPY FOR THE TREATMENT OF SOLID TUMORS - FEASIBILITY OF A 3-FOLD INCREASE IN DOSE INTENSITY WITH PERIPHERAL-BLOOD PROGENITOR CELLS AND GRANULOCYTE-COLONY-STIMULATING FACTOR

      British Journal of Cancer
    69. PETERS R; PEREZ L; JANOSSY G; PAMPALLONA S; LEJEUNE F; LEYVRAZ S
      BCL-2 PROTEIN EXPRESSION IN CD34(+) SUBPOPULATIONS

      Blood
    70. FAIN O; SITBON M; SIBONY M; FRILAY Y; MATHIEU E; LEJEUNE F; THOMAS M
      SUCCESSFUL TREATMENT OF SYSTEMIC MASTOCYT OSIS WITH INTERFERON-ALPHA

      Annales de medecine interne
    71. LEJEUNE F; LIENARD D; EGGERMONT A; KOOPS HS; KROON B
      VALUE OF ISOLATION-INFUSIONS OF THE LIMBS IN MELANOMAS AND SARCOMAS

      Annales de chirurgie
    72. FENAUX P; MOREL P; BAUTERS F; PIGUET H; MONCONDUIT M; TILLY F; DESABLENS B; CLAISSE JF; ADJIZIAN JC; POTRON G; PIGNON B; LEPORRIER M; TROUSSARD X; REMAN O; BINET JL; DIGHIERO G; MALOUM K; MERLEBERAL H; RAPHAEL M; REISENLEITER M; LINASSIER C; LAMAGNERE JP; JAUBERT J; VASSELOM C; LEBLAY R; JACOMY D; GROSBOIS B; DREYFUS B; GUILHOT F; VAUGIER G; SOUTEYRAND P; LEPEU G; TOUCHAIS AM; BOUDJERRA N; BORDESSOULE M; SCHMIDT J; FACQUETDANIS J; SEBBAN C; ALLARD C; MURGUE B; SCHVED JF; ARNAUD A; CASSASSUS P; LEPRISE PY; DOR JF; TURPIN F; SOLALCELIGNY P; TERTIAN G; BERNARD JF; JAMES JM; REIGNER A; BLANC M; RAPP MJ; BOURGEOIS JP; LEJEUNE F; SALLES B; RENOUX M; GARIN B; CAMO J; TCHERNIA G; CECCALDI J; DEVIDAS A; LEMEVELLEPOURHIET A; BRIERE J; JANVIER M; NAJEAN Y; CHEVRET S; CHASTANG C; TRAVADE P
      IS THE CHOP REGIMEN A GOOD TREATMENT FOR ADVANCED CLL - RESULTS FROM 2 RANDOMIZED CLINICAL-TRIALS

      Leukemia & lymphoma
    73. VANBEEUMEN J; DEVREESE B; GHANEM G; LEJEUNE F; DEKNOP C; FAIGNET C; TOCH I; JACQUEMOTTE F
      ELECTROSPRAY MASS-SPECTROMETRIC ANALYSIS OF NEW ALPHA-MSH ANALOGS CARRYING NITROGEN-MUSTARD AT THEIR AMINO-TERMINUS

      Peptide research
    74. AUTIER P; DORE JF; LEJEUNE F; KOELMEL KF; GEFFELER O; HILLE P; CESARINI JP; LIENARD D; LIABEUF A; JOARLETTE M; CHEMALY P; HAKIM K; KOELN A; KLEEBERG UR
      RECREATIONAL EXPOSURE TO SUNLIGHT AND LACK OF INFORMATION AS RISK-FACTORS FOR CUTANEOUS MALIGNANT-MELANOMA - RESULTS OF AN -ORGANIZATION-FOR-RESEARCH-AND-TREATMENT-OF-CANCER (EORTC) CASE-CONTROL STUDY IN BELGIUM, FRANCE AND GERMANY

      Melanoma research
    75. BEGUIN Y; LOO M; RZIK S; SAUTOIS B; LEJEUNE F; RORIVE G; FILLET G
      EFFECT OF RECOMBINANT-HUMAN-ERYTHROPOIETIN ON PLATELETS IN PATIENTS WITH ANEMIA OF RENAL-FAILURE - CORRELATION OF PLATELET COUNT WITH ERYTHROPOIETIC ACTIVITY AND IRON PARAMETERS

      European journal of haematology
    76. LEJEUNE F; LIENARD D; EGGERMONT A; KOOPS HS; ROSENKAIMER F; GERAIN J; KLAASE J; KROON B; VANDERVEKEN J; SCHMITZ P
      RATIONALE FOR USING TNF-ALPHA AND CHEMOTHERAPY IN REGIONAL THERAPY OFMELANOMA

      Journal of cellular biochemistry
    77. LIENARD D; LEJEUNE F; CHASSOT PG; CHIOLERO R; EGGIMAN P; EGGERMONT A; KOOPS HS; KROON B
      TNF-ALPHA IN ISOLATION PERFUSION FOR LIMB TUMORS

      Pathologie et biologie
    78. LEJEUNE F; LIENARD D; EGGERMONT A; KOOPS HS; KROON B; GERAIN J; ROSENKAIMER F; SCHMITZ P
      CLINICAL-EXPERIENCE WITH HIGH-DOSE TUMOR-NECROSIS-FACTOR-ALPHA IN REGIONAL THERAPY OF ADVANCED MELANOMA

      Circulatory shock
    79. MILLAN MJ; CANTON H; GOBERT A; LEJEUNE F; RIVET JM; BERVOETS K; BROCCO M; WIDDOWSON P; MENNINI T; AUDINOT V; HONORE P; RENOUARD A; LEMAROUILLEGIRARDON S; VERRIELE L; GRESSIER H; PEGLION JL
      NOVEL BENZODIOXOPIPERAZINES ACTING AS ANTAGONISTS AT POSTSYNAPTIC 5-HT1A RECEPTORS AND AS AGONISTS AT 5-HT1A AUTORECEPTORS - A COMPARATIVE PHARMACOLOGICAL CHARACTERIZATION WITH PROPOSED 5-HT1A ANTAGONISTS

      The Journal of pharmacology and experimental therapeutics
    80. AUTIER P; DORE JF; LEJEUNE F; KOELMEL KF; GEFFELER O; HILLE P; CESARINI JP; LIENARD D; LIABEUF A; JOARLETTE M; CHEMALY P; HAKIM K; KOELN A; KLEEBERG UR
      CUTANEOUS MALIGNANT-MELANOMA AND EXPOSURE TO SUNLAMPS OR SUNBEDS - ANEORTC MULTICENTER CASE-CONTROL STUDY IN BELGIUM, FRANCE AND GERMANY

      International journal of cancer
    81. RENARD N; LIENARD D; LESPAGNARD L; EGGERMONT A; HEIMANN R; LEJEUNE F
      EARLY ENDOTHELIUM ACTIVATION AND POLYMORPHONUCLEAR CELL INVASION PRECEDE SPECIFIC NECROSIS OF HUMAN-MELANOMA AND SARCOMA TREATED BY INTRAVASCULAR HIGH-DOSE TUMOR-NECROSIS-FACTOR-ALPHA (RTNF-ALPHA)

      International journal of cancer
    82. LEJEUNE F; AUDINOT V; GOBERT A; RIVET JM; SPEDDING M; MILLAN MJ
      CLOZAPINE INHIBITS SEROTONINERGIC TRANSMISSION BY AN ACTION AT ALPHA(1)-ADRENOCEPTORS NOT AT 5-HT1A RECEPTORS

      European journal of pharmacology
    83. FAIN O; ELMSELMI A; DOSQUET C; MESEURE D; LEJEUNE F; GAREL JM; THOMAS M
      HYPERCALCEMIA IN B-CELL CHRONIC LYMPHOCYTIC-LEUKEMIA

      British Journal of Haematology
    84. LEJEUNE F; GOBERT A; RIVET JM; MILLAN MJ
      BLOCKADE OF TRANSMISSION AT NMDA RECEPTORS FACILITATES THE ELECTRICALAND SYNTHETIC ACTIVITY OF ASCENDING SEROTONINERGIC NEURONS

      Brain research
    85. GOASGUEN JE; MATHIOT C; ZANDECKI M; SCHEIFF JM; BIZET M; AMAR M; LEJEUNE F; GRANGE MJ; CORBERAND JX; GENTILHOMME O; FLANDRIN G
      DEMONSTRATION THAT MORPHOLOGY IS CORRELATED TO THE PROGNOSIS IN MULTIPLE-MYELOMA

      Blood
    86. GHANEM GE; JOUBRAN C; ARNOULD R; LEJEUNE F; FRUHLING J
      LABELED POLYCYANOACRYLATE NANOPARTICLES FOR HUMAN IN-VIVO USE

      Applied radiation and isotopes
    87. BINET JL; FENAUX P; MOREL P; BAUTERS F; PIGUET H; MONCONDUIT M; TILLY F; DESABLENS B; CLAISSE JF; ADJIZIAN JC; POTRON G; PIGNON B; LEPORRIER M; TROUSSARD X; REMAN O; BINET JL; MALOUM K; MERLEBERAL H; RAPHAEL M; REISENLEITER M; LINASSIER C; LAMAGNERE JP; JAUBERT J; VASSELOM C; LEBLAY R; JACOMY D; GROSBOIS B; DREYFUS B; GUILHOT F; VAUGIER G; SOUTEYRAND P; LEPEU G; TOUCHIAS AM; BOUDJERRA N; BORDESSOULE M; TRAVADE P; SCHMIDT J; FACQUETDANIS J; SEBBAN C; ALLARD C; ROUSSET T; NAVARRO M; SCHVED JF; ARNAUD A; CASASSUS P; LEPRISE PY; DOR JF; TURPIN F; SOLALCELIGNY P; TERTIAN G; BERNARD JF; JAMES JM; REIGNER A; BLANC M; RAPP MJ; BOURGEOIS JP; LEJEUNE F; SALLES B; RENOUX M; GARIN B; CAMP J; TCHERNIA G; CECCALDI J; DEVIDAS A; LEMEVELLEPOURHIET A; BRIERE J; JANVIER M; NAJEAN Y; KERNEIS Y; COIFFIE B; DIGHIERO G; TEILLET F; GARNIER; DOIRON; STOPPA; ROGE; MAIGRE M; MAISONNEUVE; DIVINE M; CHERON; RODON; SIMON; THYSS; BRION A; EGHBALI; CHRISTIAN; CARDE; AUTRAND; PAITEL; SELIGMANN M; VIGNERON
      TREATMENT OF CHRONIC LYMPHOCYTIC-LEUKEMIA

      Bailliere's clinical haematology
    88. FAIN O; TALEB C; FRILAY Y; AUROUSSEAU MH; LEJEUNE F; THOMAS M
      THROMBOCYTOPENIC PURPURA CAUSED BY PROXIBARBAL

      La Revue de medecine interne
    89. FENAUX P; BINET JL; MALOUM K; LEPORRIER M; RAPP MJ; PIGUET H; BRION A; BOUDJERRA N; DREYFUS B; LEBLAY R; STOPPA AM; AUTRAND JP; SEBBAN C; PAITEL JF; MAISONNEUVE P; ROUSSET T; LINASSIER M; BRICE P; TRAVADE P; DIVINE M; DESABLENS B; JAUBERT J; ALLARD C; CHERON D; EGHBALI JP; CELIGNY PS; BORDESSOULE D; PIGNON B; VAUGIER G; LEJEUNE F; SALLES B; DEVIDAS M; BLANC M; MAIGRE M; REIGNER A; SIMON P; CHRISTIAN B; SCHVED JF; DOIRON P; RODON M; CARDE P; YAKOUB I; SOUTEYRAND P; RENOUX M; FACQUETDANIS J; HAMIDOU M; TURPIN F; DOR JF; FERMAND JP; VIGNERON N; GARNIER A; LELOSTER JP; CHEVRET S; CHASTING C
      COMPARISON OF FLUDARABINE, CYCLOPHOSPHAMIDE DOXORUBICIN PREDNISONE, AND CYCLOPHOSPHAMIDE DOXORUBICIN VINCRISTINE PREDNISONE IN ADVANCED FORMS OF CHRONIC LYMPHOCYTIC-LEUKEMIA - PRELIMINARY-RESULTS OF A CONTROLLED CLINICAL-TRIAL

      Seminars in oncology
    90. ECLACHE V; LUSINA D; LEJEUNE F; CASASSUS P; SMADJA N; LORTHOLARY P
      PLASMA-CELL LEUKEMIA MIMICKING ACUTE MONOCYTIC LEUKEMIA IN THE COURSEOF MULTIPLE-MYELOMA

      Nouvelle revue francaise d'hematologie
    91. DELMARMOL V; SOLANO F; SELS A; HUEZ G; LIBERT A; LEJEUNE F; GHANEM G
      GLUTATHIONE DEPLETION INCREASES TYROSINASE ACTIVITY IN HUMAN-MELANOMACELLS

      Journal of investigative dermatology
    92. LEJEUNE F; RIVET JM; GOBERT A; CANTON H; MILLAN MJ
      WAY-100,135 AND (-)-TERTATOLOL ACT AS ANTAGONISTS AT BOTH 5-HT(1A) AUTORECEPTORS AND POSTSYNAPTIC 5-HT(1A) RECEPTORS IN-VIVO

      European journal of pharmacology
    93. BEGUIN Y; LOO M; RZIK S; SAUTOIS B; LEJEUNE F; RORIVE G; FILLET G
      EARLY PREDICTION OF RESPONSE TO RECOMBINANT-HUMAN-ERYTHROPOIETIN IN PATIENTS WITH THE ANEMIA OF RENAL-FAILURE BY SERUM TRANSFERRIN RECEPTORAND FIBRINOGEN

      Blood
    94. TURLURE P; LEPRISE PY; LETORTOREC S; LINASSIER C; IFRAH N; DESABLENS B; TOURANI JM; LEJEUNE F; SENSEBE L; BRIERE JB
      ESSENTIAL THROMBOCYTHEMIA (ET) CLINICAL COURSE AND RESULTS OF A MULTICENTER PROSPECTIVE-STUDY

      Blood
    95. LEYVRAZ S; KETTERER N; VUICHARD P; VONFLIEDNER V; LEJEUNE F; SCHNEIDER P; GROB JP; BACHMANN F
      SEQUENTIAL HIGH-DOSE COMBINATION CHEMOTHERAPY WITH GRANULOCYTE-COLONY-STIMULATING FACTOR AND PERIPHERAL-BLOOD PROGENITOR CELLS IN PATIENTS WITH SOLID TUMORS - INTENSIFICATION LIMITED BY NONHEMATOLOGIC TOXIC EFFECTS

      Journal of the National Cancer Institute


ASDD Area Sistemi Dipartimentali e Documentali, Università di Bologna, Catalogo delle riviste ed altri periodici
Documento generato il 24/10/20 alle ore 14:50:36